Should you buy Repligen Corporation stock? (NasdaqGS:RGEN). Let's see how it does in our automated value investing analysis system.
Based on historical returns, we believe that Repligen Corporation can grow its free cash at a rate of about 1%. That's positive!
(Repligen Corporation stock price per share)
||RGEN Fair Price
(based on intrinsic value)
||RGEN Safety Price (based on a variable margin of safety)||$8.09|
||PE Ratio versus Sector||151% higher than other Healthcare stocks|
|PE Ratio versus Industry||11% lower than other Biotechnology stocks|
|Free Cash Flow Jitter||76%|
We believe that Repligen Corporation may be worth examining further. It's making money, which is a very positive sign. Is it on sale?
Repligen Corporation looks overpriced right now. If you're looking for a bargain in the stock market, you should probably look elsewhere for a great deal. This might still be a great stock to own—but it's not on sale right now.
Does Repligen Corporation have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.
Most Popular Articles